Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 513.00
-1.80 (-0.35%)
May 14, 2026, 5:24 PM IDT
Can-Fite BioPharma Revenue
In the year 2025, Can-Fite BioPharma had annual revenue of $405.00K USD, down -39.91%. Can-Fite BioPharma had revenue of $203.00K in the half year ending December 31, 2025, a decrease of -42.17%.
Revenue
$405.00K
Revenue Growth
-39.91%
P/S Ratio
17.09
Revenue / Employee
$81.00K
Employees
5
Market Cap
22.06M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 405.00K | -269.00K | -39.91% |
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
| Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
| Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
| Dec 31, 2016 | 165.00K | 3.00K | 1.85% |
| Dec 31, 2015 | 162.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 467.66K | -278.63K | -37.34% |
| Dec 31, 2010 | 746.29K | -125.25K | -14.37% |
| Dec 31, 2009 | 871.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 12.28M |
| Clal Biotechnology Industries | 11.55M |
| BioLineRx | 3.76M |
| XTL Biopharmaceuticals | 3.26M |
| Geffen Residence & Renewal | 78.00K |
| BioLight Life Sciences | 21.00K |
Can-Fite BioPharma News
- 1 day ago - Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital - TheFly
- 1 day ago - Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy - GlobeNewsWire
- 2 days ago - Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright - TheFly
- 14 days ago - Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - GlobeNewsWire
- 6 weeks ago - Can-Fite BioPharma files to sell 3.29M ordinary shares for holders - TheFly
- 6 weeks ago - Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs - GuruFocus
- 6 weeks ago - Can-Fite BioPharma completes enrollment in Piclidenoson study - TheFly
- 6 weeks ago - Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - GlobeNewsWire